Alterity Therapeutics to Present at the Biotech Showcase
MWN-AI** Summary
Alterity Therapeutics Limited, an innovative biotechnology company focusing on disease-modifying treatments for neurodegenerative diseases, is set to present at the Biotech Showcase hosted by Peak Asset Management and Monsoon Communications. The corporate update will be delivered by Dr. David Stamler, CEO, on September 2, 2025, in the United States and September 3, 2025, in Australia. Interested parties can register for the event through a Zoom webcast.
Alterity is primarily dedicated to developing therapies for Parkinson's disease and related disorders. Its lead candidate, ATH434, has shown promising results in clinical trials, particularly in a randomized, double-blind, placebo-controlled Phase 2 study focusing on Multiple System Atrophy (MSA), an aggressive form of Parkinsonism. The company recently reported encouraging data from an open-label Phase 2 trial involving advanced MSA patients, further solidifying ATH434's potential as a viable treatment option.
In addition to its focus on ATH434, Alterity possesses a wide-ranging drug discovery platform capable of developing new chemical compounds aimed at addressing the underlying pathologies of various neurological diseases. With operational bases in both Melbourne and San Francisco, Alterity is strategically positioned to navigate both the Australian and U.S. biotech landscapes.
The announcement, authorized by Dr. Stamler, underscores Alterity's commitment to improving the lives of those affected by neurodegenerative diseases. It also includes a forward-looking statement cautioning about the inherent risks and uncertainties involved in drug development, clinical trials, and regulatory processes, emphasizing the company's dedication to transparency with investors.
Overall, Alterity Therapeutics represents a significant player in the biopharmaceutical industry, poised to contribute meaningful advancements in the treatment of debilitating neurological disorders. For more information, visit the company's website.
MWN-AI** Analysis
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) represents an intriguing investment opportunity, especially as the company prepares to present at the upcoming Biotech Showcase on September 2, 2025. With a focus on developing disease-modifying treatments for neurodegenerative disorders, particularly Parkinson's disease and Multiple System Atrophy (MSA), the potential for ATH434 to become a cornerstone treatment is substantial.
Recent clinical trial results for ATH434 have been promising, showcasing meaningful efficacy in both randomized controlled trials and an open-label Phase 2 trial. This positive momentum is vital as investor sentiment in the biotech sector often hinges on clinical outcomes. With neurodegenerative diseases presenting largely unmet medical needs, successful development and approval of ATH434 could position Alterity favorably against competitors.
Investors should consider several key factors moving forward. First, keep an eye on the company's ability to navigate the regulatory landscape, as successful approvals are essential for commercialization. The speculative nature of biotech requires a measured approach; thus, potential investors should evaluate their risk tolerance in light of the uncertainties associated with clinical trials and product development.
Equally important is the upcoming corporate update, where CEO David Stamler will outline strategic goals and the path forward. This presentation could catalyze market interest and influence stock performance. Investors should pay close attention to any insights regarding future clinical trials, partnerships, or funding opportunities.
In summary, while Alterity Therapeutics carries inherent risks typical of clinical-stage biopharma, the significant upside potential of ATH434 could provide a compelling reason for investors to closely monitor the company, particularly leading up to and following the Biotech Showcase presentation. Engaging with real-time data and market reactions will be essential to making informed investment decisions in the rapidly evolving biotech landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia and SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Biotech Showcase hosted by Peak Asset Management and Monsoon Communications. The presentation will take place on Wednesday, 3 September 2025 in Australia; Tuesday, 2 September 2025 in the United States.
| Webcast details | |
| AUSTRALIA PARTICIPANTS: | |
| Date: | Wednesday, 3 September 2025 |
| Time: | 12:35 p.m. AEST (Sydney/Melbourne) |
| UNITED STATES PARTICIPANTS: | |
| Date: | Tuesday, 2 September 2025 |
| Time: | 7:35 p.m. Pacific Time |
| 10:35 p.m. Eastern Time | |
Register for the Zoom webcast:
https://us06web.zoom.us/webinar/register/WN_ocDL721LTS6_R4B-DG63Kw
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson’s disease and related disorders. Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ**
How does Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) plan to leverage its presence in both Melbourne and San Francisco to enhance its research and development capabilities in neurodegenerative disease treatments?
What strategic advantages does being based in Melbourne, Australia, and San Francisco, California, provide for Alterity Therapeutics Limited (ATHE) in terms of accessing funding and investors for its clinical trials?
How can stakeholders in Melbourne and San Francisco benefit from the advancements made by Alterity Therapeutics Limited (ATHE) in the Phase 2 clinical trials of ATH4for treating Multiple System Atrophy?
In what ways does Alterity Therapeutics Limited (ATHE) plan to utilize the insights gathered from the Biotech Showcase in San Francisco to bolster its drug development initiatives in Melbourne and beyond?
**MWN-AI FAQ is based on asking OpenAI questions about Alterity Therapeutics Limited (NASDAQ: ATHE).
NASDAQ: ATHE
ATHE Trading
0.17% G/L:
$3.57 Last:
4,812 Volume:
$3.58 Open:
